{"organizations": [], "uuid": "7991ac236db010f8afda18ccdce677c0c0c06708", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-dynavax-provides-new-durability-of/brief-dynavax-provides-new-durability-of-response-data-for-sd-101-in-combination-with-keytruda-in-melanoma-idUSFWN1RU13L", "country": "US", "domain_rank": 408, "title": "BRIEF-Dynavax Provides New Durability Of Response Data For SD-101 In Combination With Keytruda In Melanoma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.447, "site_type": "news", "published": "2018-04-17T21:18:00.000+03:00", "replies_count": 0, "uuid": "7991ac236db010f8afda18ccdce677c0c0c06708"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-dynavax-provides-new-durability-of/brief-dynavax-provides-new-durability-of-response-data-for-sd-101-in-combination-with-keytruda-in-melanoma-idUSFWN1RU13L", "ord_in_thread": 0, "title": "BRIEF-Dynavax Provides New Durability Of Response Data For SD-101 In Combination With Keytruda In Melanoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "dynavax", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "dynavax technologies corp", "sentiment": "negative"}, {"name": "american association for cancer research annual", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17 (Reuters) - Dynavax Technologies Corp:\n* DYNAVAX PROVIDES NEW DURABILITY OF RESPONSE DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA AT THE 2018 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING\n* DYNAVAX TECHNOLOGIES CORP - COMBINATION THERAPY WAS WELL TOLERATED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T21:18:00.000+03:00", "crawled": "2018-04-18T18:02:31.011+03:00", "highlightTitle": ""}